Cargando…
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer
Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study wa...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928882/ https://www.ncbi.nlm.nih.gov/pubmed/36623239 http://dx.doi.org/10.1200/PO.22.00104 |
_version_ | 1784888732536537088 |
---|---|
author | Cheng, Heather H. Sokolova, Alexandra O. Gulati, Roman Bowen, Deborah Knerr, Sarah A. Klemfuss, Nola Grivas, Petros Hsieh, Andrew Lee, John K. Schweizer, Michael T. Yezefski, Todd Zhou, Alicia Yu, Evan Y. Nelson, Peter S. Montgomery, Bruce |
author_facet | Cheng, Heather H. Sokolova, Alexandra O. Gulati, Roman Bowen, Deborah Knerr, Sarah A. Klemfuss, Nola Grivas, Petros Hsieh, Andrew Lee, John K. Schweizer, Michael T. Yezefski, Todd Zhou, Alicia Yu, Evan Y. Nelson, Peter S. Montgomery, Bruce |
author_sort | Cheng, Heather H. |
collection | PubMed |
description | Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study was designed to determine the feasibility of an Internet-based, patient-driven germline genetic testing approach for men with mPC. PATIENTS AND METHODS: In this prospective cohort study, men with mPC provided informed consent via an Internet-based platform and completed a questionnaire including demographics and family cancer history. Supporting medical data were also collected. Genetic testing was performed using the Color Genomics 30-gene targeted panel of cancer predisposition genes on a mailed saliva sample. Men whose test results identified a germline pathogenic or likely pathogenic variant received results by phone or telehealth genetic counseling; other participants received results by email with an option for phone-based or telehealth genetic counseling. RESULTS: As of August 18, 2021, 816 eligible men were consented, of whom 68% (551) completed genetic testing, and 8.7% (48 of 551) were found to carry a pathogenic or likely pathogenic variant in a germline DNA repair gene: CHEK2 (17), BRCA2 (15), ATM (6), NBN1 (3), BRCA1 (2), PALB2 (2), PMS2 (2), and MSH6 (1). Participants were more likely to complete the testing process if they were non-Hispanic White, married, highly educated, or from a higher-income bracket. CONCLUSION: Here, we show the feasibility of delivering germline (inherited) genetic testing by a voluntary, patient-driven, Internet-based platform to men with mPC. Preliminary results show rates of germline DNA repair mutations, consistent with other cohorts. Although feasible for some, reduced steps for participation, more dedicated diverse outreach and participant support, and identification and addressing of additional barriers is needed to ensure equitable access and optimization. |
format | Online Article Text |
id | pubmed-9928882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-99288822023-02-16 Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer Cheng, Heather H. Sokolova, Alexandra O. Gulati, Roman Bowen, Deborah Knerr, Sarah A. Klemfuss, Nola Grivas, Petros Hsieh, Andrew Lee, John K. Schweizer, Michael T. Yezefski, Todd Zhou, Alicia Yu, Evan Y. Nelson, Peter S. Montgomery, Bruce JCO Precis Oncol ORIGINAL REPORTS Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study was designed to determine the feasibility of an Internet-based, patient-driven germline genetic testing approach for men with mPC. PATIENTS AND METHODS: In this prospective cohort study, men with mPC provided informed consent via an Internet-based platform and completed a questionnaire including demographics and family cancer history. Supporting medical data were also collected. Genetic testing was performed using the Color Genomics 30-gene targeted panel of cancer predisposition genes on a mailed saliva sample. Men whose test results identified a germline pathogenic or likely pathogenic variant received results by phone or telehealth genetic counseling; other participants received results by email with an option for phone-based or telehealth genetic counseling. RESULTS: As of August 18, 2021, 816 eligible men were consented, of whom 68% (551) completed genetic testing, and 8.7% (48 of 551) were found to carry a pathogenic or likely pathogenic variant in a germline DNA repair gene: CHEK2 (17), BRCA2 (15), ATM (6), NBN1 (3), BRCA1 (2), PALB2 (2), PMS2 (2), and MSH6 (1). Participants were more likely to complete the testing process if they were non-Hispanic White, married, highly educated, or from a higher-income bracket. CONCLUSION: Here, we show the feasibility of delivering germline (inherited) genetic testing by a voluntary, patient-driven, Internet-based platform to men with mPC. Preliminary results show rates of germline DNA repair mutations, consistent with other cohorts. Although feasible for some, reduced steps for participation, more dedicated diverse outreach and participant support, and identification and addressing of additional barriers is needed to ensure equitable access and optimization. Wolters Kluwer Health 2023-01-09 /pmc/articles/PMC9928882/ /pubmed/36623239 http://dx.doi.org/10.1200/PO.22.00104 Text en © 2023 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | ORIGINAL REPORTS Cheng, Heather H. Sokolova, Alexandra O. Gulati, Roman Bowen, Deborah Knerr, Sarah A. Klemfuss, Nola Grivas, Petros Hsieh, Andrew Lee, John K. Schweizer, Michael T. Yezefski, Todd Zhou, Alicia Yu, Evan Y. Nelson, Peter S. Montgomery, Bruce Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer |
title | Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer |
title_full | Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer |
title_fullStr | Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer |
title_full_unstemmed | Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer |
title_short | Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer |
title_sort | internet-based germline genetic testing for men with metastatic prostate cancer |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928882/ https://www.ncbi.nlm.nih.gov/pubmed/36623239 http://dx.doi.org/10.1200/PO.22.00104 |
work_keys_str_mv | AT chengheatherh internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT sokolovaalexandrao internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT gulatiroman internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT bowendeborah internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT knerrsaraha internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT klemfussnola internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT grivaspetros internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT hsiehandrew internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT leejohnk internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT schweizermichaelt internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT yezefskitodd internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT zhoualicia internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT yuevany internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT nelsonpeters internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer AT montgomerybruce internetbasedgermlinegenetictestingformenwithmetastaticprostatecancer |